What is Precision Biologics?
Precision Biologics, Inc., established in February 2012 and operational by late September 2012, is a clinical-stage biotechnology corporation dedicated to pioneering therapeutic and diagnostic products for the early detection and treatment of cancer. The company's innovative approach involves developing antibody drug candidates and diagnostics designed to precisely target tumors while sparing healthy cells. Precision Biologics leverages proprietary cancer vaccines, several of which have shown promise in human trials, to create novel therapeutics. By integrating these advanced platforms with cutting-edge technologies, the company is advancing antibody therapeutics aimed at transforming cancer detection and treatment methodologies.
How much funding has Precision Biologics raised?
Precision Biologics has raised a total of $73.1M across 6 funding rounds:
Private Equity
$5.3M
Multiple Rounds
$14.6M
Private Equity
$53.1M
Debt
$150K
Private Equity (2012): $5.3M, investors not publicly disclosed
Private Equity (2013): $3.3M, investors not publicly disclosed
Unspecified (2013): $10.5M, investors not publicly disclosed
Private Equity (2013): $795K, investors not publicly disclosed
Private Equity (2015): $53.1M, investors not publicly disclosed
Debt (2020): $150K with participation from PPP
Key Investors in Precision Biologics
PPP
Public-Private Partnership
What's next for Precision Biologics?
The recent major strategic investment in Precision Biologics signals a pivotal phase for the company, likely enabling accelerated development and commercialization of its oncology pipeline. With a focus on early detection and targeted therapies, the company is well-positioned to capitalize on advancements in cancer research. Future endeavors will likely concentrate on advancing its antibody drug candidates through clinical trials and expanding its diagnostic capabilities, potentially leading to significant breakthroughs in patient care and oncology treatment paradigms. The sustained capital infusion suggests confidence from investors in Precision Biologics' long-term vision and its potential to disrupt the cancer treatment landscape.
See full Precision Biologics company page
